A Phase I Study Evaluating Safety, Pharmacokinetics, Pharmacodynamics, And Clinical Activity Of RO7119929 (TLR7 Agonist) In Participants With Unresectable Advanced Or Metastatic Hepatocellular Carcinoma, Biliary Tract Cancer, Or Solid Tumors With Hepatic Metastases

Cancer
Biliary Tract Cancer
Hepatocellular Carcinoma (HCC)

Results
Download

Study results

LPS WP41377 Final Results November 2023 Taiwan Chinese (PDF, 1.0 MB)

LPS WP41377 Final Results November 2023 Denmark Danish (PDF, 0.7 MB)

LPS WP41377 Final Results November 2023 Hong Kong Chinese (PDF, 1.3 MB)

LPS WP41377 Final Results November 2023 Korea Korean (PDF, 0.8 MB)

LPS WP41377 Final Results November 2023 Spain Spanish (PDF, 0.6 MB)

What is Clinical Research?

In clinical research, volunteers, researchers, and medical professionals work together toward a shared goal: better treatment outcomes for patients. Clinical trials are vital to their process. They are carefully designed and follow approved protocols.

A Phase I Study Evaluating Safety, Pharmacokinetics, Pharmacodynamics, And Clinical Activity Of RO7119929 (TLR7 Agonist) In Participants With Unresectable Advanced Or Metastatic Hepatocellular Carcinoma, Biliary Tract Cancer, Or Solid Tumors With Hepatic Metastases

Study results

LPS WP41377 Final Results November 2023 Taiwan Chinese (PDF, 1.0 MB)

LPS WP41377 Final Results November 2023 Denmark Danish (PDF, 0.7 MB)

LPS WP41377 Final Results November 2023 Hong Kong Chinese (PDF, 1.3 MB)

LPS WP41377 Final Results November 2023 Korea Korean (PDF, 0.8 MB)

LPS WP41377 Final Results November 2023 Spain Spanish (PDF, 0.6 MB)

What is Clinical Research?

For the latest version of this information please go to www.forpatients.roche.com

External Site

Directly contact Roche for questions

Contact the hospital directly

You are about to leave ForPatients

Thank you

Request a call back

Find participating medical centers and current study status in each of them

A Phase I Study Evaluating Safety, Pharmacokinetics, Pharmacodynamics, And Clinical Activity Of RO7119929 (TLR7 Agonist) In Participants With Unresectable Advanced Or Metastatic Hepatocellular Carcinoma, Biliary Tract Cancer, Or Solid Tumors With Hepatic Metastases

For the latest version of this information please go to www.forpatients.roche.com